Fly News Breaks for June 10, 2019
Jun 10, 2019 | 07:35 EDT
After hosting management for investor meetings in Europe and the as well the recent data presentations, Cantor Fitzgerald analyst Charles Duncan has increased conviction about the approvability of Aimmune Therapeutics' AR101 in peanut allergy. The analyst believes the "clear benefit/risk of the candidate" will fuel a "paradigm shift" in the treatment of peanut allergy for, "at least, the highest burden patient cohort" as early as Q4 of 2019. He reiterates an Overweight rating on Aimmune shares with a $45 price target.
News For AIMT From the Last 2 Days
There are no results for your query AIMT